TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1680275
Drug: Dimethindene maleate
Normalized name: dimethindene maleate
DrugBank: Dimetindene (DB08801)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dimethindene maleate (4 mg)
Study: 15715190
Drug: Oral temazepam
Normalized name: Temazepam
DrugBank: Temazepam acetate (DB14671)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral temazepam plus nebulised Lignocaine
Study: 15715190
Drug: Intravenous alfentanyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous alfentanyl
Study: 10233322
Drug: Borage oil
Normalized name: Borage oil
DrugBank: Borage oil (DB11238)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Borage oil (500 mg daily)
Study: 7595759
Drug: Cyclophosphamide (CTX)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (CTX) 2 mg/m2/d, days 1, 2; Etoposide 200-300 mg/m2/d, days 1-3; G-CSF 5-10 micrograms/d subcutaneously, days 4-18, every 4 weeks
Study: 7595759
Drug: Cyclophosphamide (CTX)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (CTX) and Etoposide with G-CSF
Study: 7761011
Drug: Sublingual buprenorphine
Normalized name: buprenorphine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual buprenorphine (0.4 mg)
Study: 24225081
Drug: Protein supplementation
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein supplementation (20 grams twice a day)
Study: 21273606
Drug: Saracatinib (175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saracatinib (175 mg daily, orally or via gastrostomy tube)
Study: 19470385
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg rapamycin
Study: 19470385
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg rapamycin
Study: 17943687
Drug: Neurocognitive enhancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurocognitive enhancement therapy (NET) + Work therapy (WT)
Study: 11483228
Drug: Extend Bar
Normalized name: Medicated Bar Soap
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extend Bar (30 g total carbohydrate, including 5 g uncooked cornstarch, 3 g protein, 3 g fat)
Study: 11483228
Drug: Placebo Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Bar (30 g total carbohydrate, 3 g protein, 3 g fat)
Study: 9489591
Drug: Troglitazone (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone (400 mg orally) with food
Study: 9489591
Drug: Troglitazone (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone (400 mg orally) after food
Study: 9489591
Drug: Troglitazone (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone (400 mg orally) fasting
Study: 29316885
Drug: Monthly cash
Normalized name: Cashew
DrugBank: Cashew (DB10653)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly cash transfer (unconditional)
Study: 28843616
Drug: Pirfenidone (2.403
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirfenidone (2.403 mg/daily) for one year
Study: 7639372
Drug: methohexital (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: methohexital (0.5 mg/kg)
Study: 12389657
Drug: Closure of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closure of subcutaneous fat layer with a running 3‐0 plain suture
Study: 10429836
Drug: Zanamivir 4
Normalized name: Zanamivir
DrugBank: Zanamivir (DB00558)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zanamivir 4 mg intravenously in healthy participants and those with mild/moderate renal impairment
Study: 8538187
Drug: 4-HPR at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-HPR at a dose of 200 mg po for one year in basal cell carcinoma study
Study: 2147161
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (100 mg)
Study: 2147161
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of medroxyprogesterone acetate and tamoxifen (2 x 10 mg)
Study: 28430384
Drug: Intranasal naloxone
Normalized name: NALOXONE RESCUE KIT INTRANASAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal naloxone 8 mg/0.4 ml
Study: 28430384
Drug: Intranasal naloxone
Normalized name: NALOXONE RESCUE KIT INTRANASAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal naloxone 16 mg/0.4 ml
Study: 28430384
Drug: Sublingual naloxone
Normalized name: buprenorphine / naloxone Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual naloxone 16 mg/ml
Study: 26589371
Drug: Essential phospholipid
Normalized name: Egg Phospholipids
DrugBank: Egg phospholipids (DB14233)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Essential phospholipid (EPL) 1800 mg/day for 24 weeks, followed by 900 mg for 48 weeks
Study: 24020649
Drug: Adenosine and
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine and Isoproterenol administration with no further ablation for non-PV foci that did not induce AF (group 1C).
Study: 24020649
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group undergoing PVAI without drug challenge (group 2).
Study: 21857276
Drug: Single sciatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single sciatic nerve block followed by saline infusion and continuous lumbar plexus block (group C, n = 19)
Study: 19232032
Drug: S100 +
Normalized name: ADU-S100
DrugBank: ADU-S100 (DB14722)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S100 + M2000 (sitagliptin 50 mg b.i.d. + metformin 1000 mg b.i.d.)
Study: 19232032
Drug: S100 +
Normalized name: ADU-S100
DrugBank: ADU-S100 (DB14722)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S100 + M1000 (sitagliptin 50 mg b.i.d. + metformin 500 mg b.i.d.)
Study: 19232032
Drug: M1000 (metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: M1000 (metformin 500 mg b.i.d.)
Study: 19232032
Drug: S100 (sitagliptin
Approvals — FDA: no, EMA: no, PMDA: no
Description: S100 (sitagliptin 100 mg q.d.)
Study: 19232032
Drug: PBO/M2000 (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBO/M2000 (placebo switched to metformin 1000 mg b.i.d. at week 24)
Study: 17515742
Drug: Naprapathic manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naprapathic manual therapy (Index Group)
Study: 11594926
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg remacemide hydrochloride
Study: 11594926
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg remacemide hydrochloride
Study: 9561428
Drug: Binge eating
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Binge eating disorder treatment
Study: 2644750
Drug: Indomethacin (25‐50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (25‐50 mg bolus plus infusion, 5‐7.5 mg h‐1)
Study: 26101038
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (physical therapy)
Study: 23529989
Drug: Dunaliella bardawil
Normalized name: Dunaliella salina extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dunaliella bardawil capsules
Study: 23529989
Drug: Placebo (starch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (starch powder capsules)
Study: 9184370
Drug: Empirical prescribing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical prescribing of antibiotics
Study: 3283783
Drug: Amitriptyline (median
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (median dose 125 mg daily)
Study: 23324599
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (VD) 1,000 IU daily for four months
Study: 14603195
Drug: Miniaturized sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miniaturized sequential device (CECT group)
Study: 14603195
Drug: Standard calf-length
Normalized name: thymus gland-calf
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard calf-length sequential IPC device (SCD group)
Study: 23536584
Drug: Lixisenatide morning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lixisenatide morning injection
Study: 23536584
Drug: Lixisenatide evening
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lixisenatide evening injection
Study: 17240493
Drug: DTaP-HepB-IPV vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP-HepB-IPV vaccine coadministered with PCV and Hib
Study: 17240493
Drug: Separate administration
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate administration of DTaP, HepB, IPV, Hib, and PCV
Study: 9305417
Drug: Haloperidol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (0.5 or 1.0 mg)
Study: 31919583
Drug: Quinoa biscuits
Normalized name: quinoa oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinoa biscuits (15 g daily for 4 weeks)
Study: 30594190
Drug: Chronic pain
Normalized name: Aspirin 81 mg ORAL TABLET [Chronic Pain/Fever Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic pain self-management course (2.5-h weekly sessions for 6 weeks)
Study: 30594190
Drug: Low-impact outdoor
Normalized name: Cleartime Indoor & Outdoor Allergies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-impact outdoor physical activity (1-h weekly sessions for 6 weeks)
Study: 27055527
Drug: Eslicarbazepine acetate
Normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eslicarbazepine acetate monotherapy (1200 or 1600 mg once daily)
Study: 20565345
Drug: High-dose cholecalciferol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cholecalciferol 50,000 IU daily for 10 days
Study: 20565345
Drug: Low-dose cholecalciferol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cholecalciferol 3000 IU daily for 30 days, followed by 1000 IU daily for 60 days
Study: 8780337
Drug: 2.5 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 g/d eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA)
Study: 8780337
Drug: 7.7 g
Normalized name: somatropin 13 % (1 gram/7.7 gram) MISCELL POWDER (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.7 g EPA + DHA/d
Study: 1452381
Drug: Hydrochlorothiazide 6.25
Normalized name: hydrochlorothiazide 6.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide 6.25 mg
Study: 3881175
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose human leukocyte alpha-interferon (10 X 10(6) units/day for 28 days)
Study: 27438995
Drug: Raloxifene hydrochloride,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene hydrochloride, 120 mg/d
Study: 20713879
Drug: IMC‐A12 monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMC‐A12 monotherapy (10 mg/kg IV every 2 weeks)
Study: 20713879
Drug: IMC‐A12 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMC‐A12 plus cetuximab (10 mg/kg IMC-A12 and 500 mg/m2 cetuximab IV every 2 weeks)
Study: 18413068
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate 150 mg/day (days 3 to 7) + oral phytoestrogen (Cimicifuga racemosa) 120 mg/day (days 1 to 12)
Study: 16190795
Drug: Extended-release methylphenidate
Normalized name: methylphenidate Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release methylphenidate (ER-MPH) 20 mg
Study: 16190795
Drug: OROS-methylphenidate (OROS-MPH)
Normalized name: Oro Clense
Approvals — FDA: no, EMA: no, PMDA: no
Description: OROS-methylphenidate (OROS-MPH) 36 mg
Study: 2181701
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron 2 mg/kg/d until the age of 6 months
Study: 2181701
Drug: Intramuscular iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular iron dextran 100 mg between the ages of 6 and 8 weeks
Study: 111279
Drug: LAAM (1-Alpha-acetylmethadol)
Normalized name: LAAM
DrugBank: Levacetylmethadol (DB01227)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAAM (1-Alpha-acetylmethadol) administered every other day
Study: 111279
Drug: Methadone administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone administered every day
Study: 25180869
Drug: High-dose terlipressin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose terlipressin (1 mg/6-8 h, n=27)
Study: 25180869
Drug: Low-dose terlipressin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose terlipressin (1 mg/12 h, n=29)
Study: 16210047
Drug: Tacrolimus (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus (0.1 mg/kg weight)
Study: 10695777
Drug: artesunate (total
Approvals — FDA: no, EMA: no, PMDA: no
Description: artesunate (total dose of 12 mg/kg over five days)
Study: 19813462
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (alendronate 70 mg tablets)
Study: 1725151
Drug: Cefixime 8
Normalized name: cefixime 8 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefixime 8 mg/kg once daily at bedtime for 10 days
Study: 1725151
Drug: Amoxicillin 50
Normalized name: amoxicillin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 50 mg/kg/day in 3 divided doses for 10 days
Study: 1906097
Drug: Cefixime and
Normalized name: cefixime and ornidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefixime and Amoxicillin
Study: 30083110
Drug: Cinemotion training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinemotion training (delivered in weekly group sessions)
Study: 29282952
Drug: Needle knife
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Needle knife therapy combined with rotation traction manipulation
Study: 20473733
Drug: Chinese medicine
Normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medicine comprehensive therapy
Study: 20473733
Drug: Chemotherapeutic agents
Normalized name: Other chemotherapeutics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapeutic agents with iodized oil chemo-embolization and analgesics
Study: 16202258
Drug: Oral Leflunomide
Normalized name: Leflunomide
DrugBank: Leflunomide (DB01097)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Leflunomide (LEF)
Study: 8966308
Drug: Pentamidine 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentamidine 4 mg/kg/every 2 days for 8 applications
Study: 1898891
Drug: Low-dose follicle-stimulating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose follicle-stimulating hormone (FSH)
Study: 29558967
Drug: Juanbi pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Juanbi pill
Study: 24768543
Drug: Topical Tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical Tranexamic Acid (2.0g)
Study: 24768543
Drug: Intravenous Tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Tranexamic Acid (10mg/kg)
Study: 24768543
Drug: Topical Tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical Tranexamic Acid
Study: 20051288
Drug: Oral ferrous
Normalized name: ferrous fumarate Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ferrous sulphate 600 mg/day
Study: 8471679
Drug: Oxaprotiline (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaprotiline (a highly specific inhibitor of NA uptake)
Study: 6361788
Drug: Suprofen 200
Normalized name: suprofen 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suprofen 200 mg
Study: 3896016
Drug: Cosalgesic (dextropropoxyphene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cosalgesic (dextropropoxyphene hydrochloride 65 mg and paracetamol 650 mg)
Study: 29739384
Drug: Group Cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Cognitive Behavioural Therapy (CBT) intervention plus Treatment as Usual (TAU)
Study: 24916165
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation (50 mg Fe as FeSO₄, 4 days/week for 38 weeks)
Study: 15531007
Drug: Duloxetine 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 120 mg/d
Study: 11879862
Drug: 5 mg/day
Normalized name: Lyllana 0.05 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/day enalapril for 2 years
Study: 3541062
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (controls)
Study: 10439732
Drug: Rapacuronium 1
Normalized name: rapacuronium 100 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapacuronium 1 mg/kg
Study: 10439732
Drug: Rapacuronium 2
Normalized name: rapacuronium 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapacuronium 2 mg/kg
Study: 10439732
Drug: Rapacuronium 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapacuronium 3 mg/kg
Study: 8537687
Drug: 23-valent pneumococcal
Normalized name: Streptococcus pneumoniae type 1 capsular polysaccharide antigen
DrugBank: Streptococcus pneumoniae type 1 capsular polysaccharide antigen (DB10319)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23-valent pneumococcal polysaccharide vaccine
Study: 323297
Drug: Methylprednisolone sodium
Normalized name: methylPREDNISolone sodium phosphate
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone sodium phosphate (80 mg, multiple doses)
Study: 29205786
Drug: Semaglutide 0.5
Normalized name: semaglutide 0.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semaglutide 0.5 mg subcutaneous dose
Study: 27521353
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (LMWH) for 2 weeks
Study: 2068469
Drug: Aztreonam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aztreonam (1 g intravenously 30 minutes before surgery and 8 and 16 hours after surgery)
Study: 2068469
Drug: Gentamicin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin (80 mg intravenously 30 minutes before surgery and 8 and 16 hours after surgery)
Study: 30888478
Drug: Clarithromycin 500
Normalized name: clarithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 500 mg daily for 6 months
Study: 22475593
Drug: Pyronaridine-artesunate (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyronaridine-artesunate (180 mg pyronaridine and 60 mg artesunate, administered once daily for 3 days)
Study: 22475593
Drug: Mefloquine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine plus artesunate (250 mg mefloquine and 100 mg artesunate, administered once daily for 3 days)
Study: 20813564
Drug: 25% podophyllin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25% podophyllin resin with 1% penciclovir cream (PP)
Study: 16258087
Drug: Tamoxifen (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (30 mg daily for 5 years)
Study: 1954079
Drug: Frusemide 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frusemide 40 mg
Study: 8172095
Drug: 1,25-dihydroxyvitamin D
Normalized name: 1,25-dihydroxyvitamin D
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,25-dihydroxyvitamin D (1,25(OH)2D) treatment (1 micrograms/d for 4 d)
Study: 3351700
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg intravenous metoclopramide
Study: 31436322
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (nCT) with cisplatin 100 mg/m2 on day 1 and 750 mg/m2 5-fluorouracil over 24 hours on days 1-5 for three 21-day cycles
Study: 23171567
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT), n = 60, energy dose of 6 J per tender point, treated three times per week for four weeks (total of 12 sessions).
Study: 23171567
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT), n = 60.
Study: 17397005
Drug: Loop electrosurgical
Normalized name: LOOP OSTOMY ROD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loop electrosurgical excision procedure (LEEP) for CIN3 treatment
Study: 15105817
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no intravitreal injection)
Study: 12498843
Drug: Heparin-surface-modified PMMA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-surface-modified PMMA (HSM PMMA) IOL
Study: 9834303
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and warfarin
Study: 8014643
Drug: Miller Galante
Normalized name: Hongo Killer
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Miller Galante I (MG I)
Study: 6777458
Drug: Clovoxamine 50
Normalized name: fluvoxamine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clovoxamine 50 mg
Study: 29363217
Drug: Imipramine 75
Normalized name: trimipramine 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine 75 mg
Study: 31813228
Drug: Lay counselor-delivered
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lay counselor-delivered problem-solving therapy
Study: 23588864
Drug: Tramadol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (200 mg added to treatment)
Study: 23588864
Drug: Transdermal fentanyl
Normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Transdermal fentanyl (TDF) (initial dose of 25 µg/h, increased by 25 µg/h as needed)
Study: 19065670
Drug: Adefovir 10
Normalized name: adefovir 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adefovir 10 mg/day
Study: 17006279
Drug: Cold-adapted influenza
Normalized name: INFLUENZA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold-adapted influenza vaccine, trivalent (CAIV-T)
Study: 7493436
Drug: Octreotide (subcutaneous)
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Octreotide (subcutaneous)
Study: 2966565
Drug: Sequential intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential intravenous streptokinase and PTCA
Study: 2966565
Drug: Intravenous streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous streptokinase with angioplasty
Study: 30777027
Drug: Patient-controlled intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled intravenous analgesia (PCIA)
Study: 18710603
Drug: Sex, BMI,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sex, BMI, contraceptive pill use (as variables)
Study: 8951977
Drug: Caffeine (3.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (3.3 mg/kg, equivalent to 2‐3 cups of coffee)